Resected pancreatic cancer treated pre-operatively with chemotherapy is enriched for cells that co-express GATA6, KRT17 and CYP3A. Persistent expression of GATA6hi and KRT17hi is associated with poor survival after treatment with mFOLFIRINOX, but not gemcitabine. CYP3A-expressing drug detoxification pathways metabolize the prodrug irinotecan, a constituent of mFOLFIRINOX, leading to persistent drug tolerance.
This is a preview of subscription content, log in via an institution to check access.
References
Springfeld, C. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 20, 318–337 (2023). A review article that presents a comprehensive overview of current treatment modalities for PDAC.
Ghaneh, P. et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRONOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 157–168 (2022). This paper reports the results of the ESPAC-5 randomized phase 2 neoadjuvant trial.
Bailey, P. et al. Refining the treatment of pancreatic cancer from big data to improved individual survival. Function (Oxf). 4, zqad011 (2023). A review article that provides a comprehensive overview of current and emerging pancreatic cancer therapy, PDAC subtypes and tumor cell plasticity.
Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 231–240 (2020). This paper provides the first clues that PDAC cells exist in a transcriptional continuum with ‘hybrid’ cells expressing genes common to both the classical and basal-like subtypes.
Raghavan, S. et al. Microenvironment drives cell state, plasticity and drug response in pancreatic cancer. Cell 184, 6119–6137 (2021). This paper provides the first comprehensive evidence that PDAC cells exhibit plasticity and can transition between classical, hybrid and basal-like states.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Zhou, X. et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat. Cancer https://doi.org/10.1038/s43018-023-00628-6 (2023).
Rights and permissions
About this article
Cite this article
Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC. Nat Cancer 4, 1226–1227 (2023). https://doi.org/10.1038/s43018-023-00629-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00629-5
- Springer Nature America, Inc.